3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Breast
1
Conditions
Breast Neoplasms
10
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Meningeal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Cancer Metastatic
1
Brain Neoplasms
1
Interventions
Trastuzumab
18
Radiosurgery
15
Capecitabine
13
Lapatinib
11
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
7
Temozolomide
6
tucatinib
4
pembrolizumab
4
paclitaxel-Angiopep-2 conjugate
4
eribulin
4
Vinorelbine
4
Specimen Handling
4
Paclitaxel
4
Methotrexate
4
Cisplatin
4
sacituzumab govitecan
3
pyrotinib
3
abemaciclib
3
Radiation
3
Fluorodeoxyglucose F18
3
pertuzumab
2
palbociclib
2
neratinib
2
durvalumab
2
cediranib
2
cabazitaxel
2
Sodium Chloride
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
patritumab deruxtecan
×
Breast
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled